[Cytomegalovirus and pregnancy: Challenges and perspectives].

Authors

Charles Egloff, Christelle Vauloup-Fellous, Olivier Picone

Published in

La Revue du praticien. Volume 76. Issue 6. Pages 622-629.

Abstract

Cytomegalovirus (CMV), a member of the Herpesviridae family, is the leading infectious cause of congenital neurosensory impairment. This article reviews the key clinical aspects essential for its management during pregnancy and discusses upcoming challenges and future perspectives. In recent years, valacyclovir has demonstrated its efficacy in reducing the risk of maternal-fetal transmission following seroconversion during pregnancy. Based on this evidence, the health-economic evaluation of systematic CMV screening during the first trimester of pregnancy strongly supports its widespread implementation, despite its inability to address secondary infections. Since June 2025, the French National Authority for Health (HAS) has recommended routine screening for CMV infection during the first trimester of pregnancy (for pregnant women whose serostatus is negative or unknown). Emerging antivirals, such as valganciclovir and letermovir, currently under evaluation, could expand treatment options. Finally, research on a vaccine are ongoing, it holds the potential to revolutionize the long-term management of this infection.

PMID:
42439144
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.